



**Assessment of Cerebrovascular Resistance  
Index in Chronic Liver disease Patients  
with and without Hepatic Encephalopathy  
using Transcranial Doppler  
Ultrasonography**

*Thesis*

Submitted for Partial Fulfillment of Master Degree  
In Internal Medicine

*By*

**Moataz Bellah Hussien Ali**  
(M.B., B. Ch.)

*Supervised by*

**Prof. Dr. Sameh Mohammed Ghaly**

Professor of Internal Medicine  
Faculty of Medicine - Ain shams University

**Prof. Dr. Sherif Monier Mohamed**

Professor of Internal Medicine  
Faculty of Medicine - Ain shams University

**Dr. Hossam Samir Elbaz**

Lecturer of Internal Medicine  
Faculty of Medicine - Ain shams University

**Faculty of Medicine  
Ain Shams University  
2015**

**بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ**

(... رَبِّ أَوْزِعْنِي أَنْ أَشْكُرَ نِعْمَتَكَ

الَّتِي أَنْعَمْتَ عَلَيَّ وَعَلَى وَالِدَيَّ

وَأَنْ أَعْمَلَ صَالِحاً تَرْضَاهُ

وَأَذِّنْ لِي بِرَحْمَتِكَ فِي

عِبَادِكَ الصَّالِحِينَ]

**صدق الله العظيم**

النمل.. آية رقم ١٩



## Acknowledgement

*First of all I wish to express my thanks to **ALLAH**, to the Most Merciful and the Most Grateful for His generous care throughout my life.*

*I wish to express my deepest gratitude to **Prof. Dr. Sameh Mohammed Ghaly**, Prof. of Internal Medicine, Faculty of Medicine, Ain-Shams University for his constant guidance, Constructive supervision and following the performance and progress of this thesis. I much benefited from his creative thinking.*

*I would also like to express my gratitude and appreciation toward **Prof. Dr. Samia Ashour Mohamed**, Head of Neurology department, Faculty of Medicine, Ain-Shams University for her cooperative sharing in our study. And her kind approval for doing this thesis study.*

*I am greatly indebted to **Prof. Dr. Sherif Monier Mohamed**, Prof. of Internal Medicine, Faculty of Medicine, Ain-Shams University for his constant guidance and valuable opinions, suggestions and constructive criticism.*

*I am greatly indebted to **Dr. Hossam Samir Elbaz**. Lecturer of Internal Medicine, Faculty of Medicine, Ain-Shams University for his great help and valuable assistance in reading, revision and discussion of all results of this thesis.*

*I would also like to express my deepest gratitude and appreciation toward. **Dr. Ahmed Mohamed El-Sadek**, Lecturer of Neurology department, Faculty of Medicine, Ain-Shams University for his effective work and sharing in interpretation and analysis of the results of this thesis.*



**Moataz Bellah Hussien Ali**

## **Contents**

<i><b>Subject</b></i>	<i><b>Page No.</b></i>
<b>List of Abbreviations .....</b>	<b>i</b>
<b>List of Tables .....</b>	<b>iii</b>
<b>List of Figures .....</b>	<b>vii</b>
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the Work .....</b>	<b>4</b>
<b>Review of Literature</b>	
-Liver Cirrhosis .....	5
-Hepatic Encephalopathy .....	29
-Transcranial Doppler Ultrasonography .....	49
<b>Patients and Methods.....</b>	<b>60</b>
<b>Results.....</b>	<b>65</b>
<b>Discussion .....</b>	<b>97</b>
<b>Summary .....</b>	<b>107</b>
<b>Conclusion.....</b>	<b>111</b>
<b>Recommendation.....</b>	<b>112</b>
<b>References .....</b>	<b>113</b>
<b>Arabic Summary .....</b>	<b>—</b>

## **List of Abbreviations** *(Cont.)*

<b>ACA</b>	: Anterior Cerebral Artery
<b>AIH</b>	: Autoimmune Hepatitis
<b>ALD</b>	: Alcoholic Liver Disease
<b>ALT</b>	: Alanin Transferase
<b>ANA</b>	: Anti Nuclear Antibodies
<b>ASMA</b>	: Anti Smooth Muscle Antibodies
<b>AST</b>	: Aspartate Transaminase
<b>AASLD</b>	: American Association for the study of liver Diseases
<b>CBC</b>	: Complete Blood Count
<b>CBF</b>	: Cerebral blood flow
<b>CHC</b>	: Chronic Hepatitis C
<b>HBV</b>	: Hepatitis B virus
<b>HCV</b>	: Hepatitis C Virus
<b>HE</b>	: Hepatic Encephalopathy
<b>HH</b>	: Hereditary Hemochromatosis
<b>HRS</b>	: Hepatorenal Syndrome
<b>HSC</b>	: Hepatic Stellate Cells
<b>ICH</b>	: Intracranial hemorrhage
<b>IDU</b>	: Intravenous Drug Users
<b>INR</b>	: International Normalized Ratio
<b>LKM1</b>	: Anti Liver Kidney Microsomal Antibodies
<b>MCA</b>	: Middle Cerebral Artery
<b>MHE</b>	: Minimal hepatic encephalopathy

### **List of Abbreviations** *(Cont.)*

<b>NAFLD</b>	: Non Alcoholic Fatty Liver Disease
<b>OLT</b>	: Orthotopic Liver Transplantation
<b>PCA</b>	: Posterior cerebral artery
<b>PI</b>	: Pulsatility Index
<b>PSC</b>	: Primary Sclerosing Cholangitis
<b>RI</b>	: Resistance Index
<b>SBP</b>	: Spontaneous Bacterial Peritonitis
<b>SD</b>	: Standard Deviation
<b>TCCD</b>	: Transcranial Color Coded Duplex Sonography
<b>TCD</b>	: Transcranial Doppler Ultrasonography
<b>TIPS</b>	: Trans Jugular Intrahepatic Portosystemic Shunt
<b>WD</b>	: Wilson's Disease
<b>WHC</b>	: West Haven Classification

## List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (1):</b>	Causes of liver cirrhosis.....	24
<b>Table (2):</b>	Indications and contraindications of liver transplantation.....	28
<b>Table (3):</b>	Accepted Guidelines for a Normal TCD Study .....	52
<b>Table (4):</b>	Effects of Different Physiological States on TCD Flow Velocity .....	59
<b>Table (5):</b>	Distribution of the studied groups: .....	66
<b>Table (6):</b>	Comparison between group I (control) and group II & III (cases) as regard ages .....	67
<b>Table (7):</b>	Comparison between group II and group III (cases) as regard ages: .....	68
<b>Table (8):</b>	Mean and standard deviation of pulse, blood pressure and temperature in the three groups.....	68
<b>Table (9):</b>	Comparison between group (II), group (III) as regard P values of pulse, blood pressure and temperature: .....	69
<b>Table (10):</b>	The mean hemoglobin level (gm/dl) in our study groups.....	70
<b>Table (11):</b>	Comparison between group I (control) & group II, III (cases) as regards hemoglobin level (gm/dl).....	71

## **List of Tables (Cont.)**

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (12):</b>	Comparison between group I (control) & group II, III (cases) as regards white blood cells count $\times 10^3/\text{cmm}$ .....	71
<b>Table (13):</b>	Comparison between group I (control) & group II, III (cases) as regards Partial Thromboplastin Time (P.T.T) .....	72
<b>Table (14):</b>	Comparison between group II & group III as regards Partial Thromboplastin Time (P.T.T).....	72
<b>Table (15):</b>	Comparison between group I (control) & group II, III (cases) as regards (INR): .....	73
<b>Table (16):</b>	Comparison between group II & group III as regards (INR):.....	73
<b>Table (17):</b>	The median (25-75 P) of liver enzymes and bilirubin in group (I). .....	74
<b>Table (18):</b>	The median (25-75 P) of liver enzymes and bilirubin in group (II).....	75
<b>Table (19):</b>	The median (25-75 P) of liver enzymes and bilirubin in group (III).....	75
<b>Table (20):</b>	Comparison between group I (control) & group II, III (cases) as regard median (ALT, AST, Total and direct Bilirubin). .....	77
<b>Table (21):</b>	Comparison between group II & group III as regard median (ALT, AST, Total and direct Bilirubin). .....	78



## **List of Tables (Cont.)**

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (22):</b>	Comparison between group I (control) and group II & III (cases) as regards mean of serum albumin (gm/dl). .....	78
<b>Table (23):</b>	Comparison between group II and III as regards serum albumin level (gm/dl). .....	79
<b>Table (24):</b>	The median (25-75 P) of serum creatinin level in studied groups. ....	80
<b>Table (25):</b>	Comparison between group I (control) & group II, III (cases) as regards serum creatinin. ....	80
<b>Table (26):</b>	Comparison between group II and group III as regards serum creatinin (gm/dl) .....	81
<b>Table (27):</b>	Descriptive statistics of TCD findings for right and left middle cerebral artery in group I (control). ....	81
<b>Table (28):</b>	Descriptive statistics of TCD findings for right and left middle cerebral artery in group II. ....	82
<b>Table (29):</b>	Descriptive statistics of TCD findings for right and left middle cerebral artery in group III. ....	82
<b>Table (30):</b>	Comparison between group II and group III as regards TCD parameters for middle cerebral artery (MCA). ....	82

## **List of Tables** *(Cont.)*

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (31):</b>	Comparison between group I (control) and group II & III as regards TCD parameters for middle cerebral artery (MCA). .....	84
<b>Table (32):</b>	Correlation between resistance index of right MCA with other studied parameters in group II&III (cases). .....	86
<b>Table (33):</b>	Correlation between pulsatility index of right MCA with other studied parameters in group II&III (cases). .....	88
<b>Table (34):</b>	Correlation between Resistance index of left MCA with other parameters were studied in group II&III (cases). .....	90
<b>Table (35):</b>	Correlation between Pulsatility index of left MCA in to other studied parameters in group II&III (cases). .....	91

## List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (1):</b>	TCD probe positions over different acoustic windows of the skull.....	50
<b>Figure (2):</b>	TCD screen waveform with velocity scale.....	51
<b>Figure (3):</b>	Gender distribution of the studied groups. ....	66
<b>Figure (4):</b>	Comparison between group I (control) and group II & III (cases) as regard ages .....	67
<b>Figure (5):</b>	The three groups as regard hemoglobin level (gm/dl).....	70
<b>Figure (6):</b>	Comparison between group I, group II & group III as regards (INR). ....	74
<b>Figure (7):</b>	Comparison between group I, group II & group III as regards the median of ALT level (U/L).....	76
<b>Figure (8):</b>	Comparison between group I, group II & group III as regards the median of AST level (U/L).....	76
<b>Figure (9):</b>	Comparison between group I, group II & group III as regards the median of bilirubin levels (mg/dl) .....	77
<b>Figure (10):</b>	Comparison between group I, group II & group III as regards the mean albumin levels (gm/dl). ....	79
<b>Figure (11):</b>	Resistance index R.I of Right & Left Middle cerebral artery (MCA) in different groups of the study.....	85

## **List of Figures (Cont.)**

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (12):</b>	Pulsatility index Right and Left MCA In different groups of the study.....	85
<b>Figure (13):</b>	Results of diagnostic validity test of middle cerebral artery resistance index and its best cut-off value.....	93
<b>Figure (14):</b>	Results diagnostic validity test of middle cerebral artery pulsatility index and the best cut-off value. ....	94
<b>Figure (15):</b>	ROC curve analysis showing the diagnostic performance of resistance index (R.I) for discriminating patients with encephalopathy from those without encephalopathy. ....	95
<b>Figure (16):</b>	ROC curve analysis showing the diagnostic performance of pulsatility index (P.I) for discriminating patients with encephalopathy from those without encephalopathy. ....	96

## Introduction

Liver cirrhosis and chronic liver disease were the 10<sup>th</sup> leading cause of death for men and the 12th for women in the United States in 2001, killing about 27,000 people each year. Worldwide, an estimated 130–170 million people have HCV infection. HCV prevalence is highest in Egypt at >10% of the general population (*Hajarizadeh et al., 2013*).

In Egypt liver cirrhosis and chronic liver disease is a major problem. the commonest underlying cause is HCV infection, the highest prevalence rate of HCV infection in the world have been reported among Egyptian blood donor and seroprevalence rates of 30-40% in villagers (*Gueera et al., 2012*).

Hepatic encephalopathy is a brain dysfunction caused by liver insufficiency and/or portosystemic shunting. It manifest as a wide spectrum of neuropsychiatric abnormalities ranging from subclinical alterations to coma, after exclusion of other known brain disease (*Vilstrup et al., 2014*).

The development of hepatic encephalopathy negatively impacts patient survival. The occurrence of encephalopathy severe enough to lead to hospitalization is associated with a survival probability of 42% at 1 year of follow-up and 23% at 3 years as reported in (*Khungar and Poordad, 2012*) study.

So in our study, we tried to explore pathophysiological etiologies in developing hepatic encephalopathy and find a different explanation other than the old theories like hyperammonemia, GABA theory; which is cerebral vascular impairment in developing hepatic encephalopathy and put in mind its correction in treatment plan.

So the current study finding cut-off value for cerebrovascular resistive indices may help in screening chronic liver disease patients and prediction of possibility for developing encephalopathy.

Cerebral auto-regulation has been reported to be preserved in patients with liver cirrhosis. But in patients with hepatic encephalopathy cerebral autoregulation is impaired (*Strauss et al., 2000*).

Transcranial Doppler (TCD) is the only non invasive real-time neuro-imaging modality for the evaluation of characteristics of blood flow in basal intracerebral vessels. TCD has been rapidly evolving from a simple non invasive diagnostic tool to an imaging modality with broad spectrum of clinical applications (*Tsivgoulis et al., 2009*).

Resistance index (RI), which is a measure of pulsatile blood flow that reflects the resistance to blood flow caused by micro vascular bed distal to the site of measurement.

Pulsatility index (PI), which assesses arteriolar vascular integrity (*Ulises et al., 2014*).

The mean cerebral blood velocity is not a reliable parameter to detect the alteration of cerebral blood flow. It was found that the cerebral vascular resistance increased with the severity of liver cirrhosis (*Sugano et al., 2001*).

The cerebral pulsatility and resistive indices changed in parallel with the severity of hepatic encephalopathy. Doppler parameters significantly increased when hepatic encephalopathy worsened. Increased cerebral vascular resistance might reflect reversible functional changes rather than irreversible anatomical damage. In patients with acute or chronic liver failure cerebral perfusion, determined by TCD, was increased and levels of ammonia and bilirubin were reduced following treatment with the molecular adsorbents recirculating system (an extracorporeal liver support device). Hepatic encephalopathy and cerebral blood flow, determined by transcranial Doppler, improved by liver dialysis treatment (*Huang et al., 2003*).